Biohaven Ltd.'s SEC filings document the formal disclosures of a British Virgin Islands clinical-stage biopharmaceutical company listed under BHVN. The filing record includes Form 8-K reports for operating results, Regulation FD presentations, clinical and regulatory pipeline updates, and material equity financing events involving common shares.
Proxy and annual-meeting filings cover director elections, auditor ratification, executive compensation votes and shareholder governance matters. Registration-related disclosures and prospectus supplements describe shelf registration mechanics, at-the-market equity distribution arrangements, underwriting agreements and common-share issuance activity that support the company's development-stage funding strategy.
Biohaven Ltd. (BHVN) reported that officer Kimberly Gentile, SVP, Clinical Operations, had a stock option grant reported in her name for 1,000 options to purchase Biohaven common shares at an exercise price of $12.34 per share, expiring September 15, 2036. The option was granted in connection with her son's employment and is held indirectly "By Son", with vesting in four equal installments on September 15 of 2026, 2027, 2028 and 2029, subject to his continuous service. Gentile disclaims beneficial ownership of all securities held by her son, and no Rule 10b5-1 trading plan is reported.
Biohaven Ltd. (BHVN) reports that the U.S. FDA issued a partial clinical hold on the BHV-7000 epilepsy program on September 4, 2026, pausing new patient enrollment while additional nonclinical studies further characterize a specific rodent metabolite.
Dosing continues for more than 600 already randomized patients across the BHV-7000 program, including BHV7000-303, which is fully enrolled, with topline data still expected in the second half of 2026. Over 1,200 participants have received BHV-7000 to date, and the safety profile has generally been described as safe and well-tolerated. BHV7000-302 and the open-label extension study will keep dosing but will not enroll new patients until the additional nonclinical data are available.
Separately, on August 26, 2026, Biohaven’s subsidiary Biohaven Bioscience Ireland Limited entered into a License Agreement under which SK Biopharmaceuticals will receive an exclusive, royalty-bearing, worldwide license to Biohaven’s Kv7 ion channel platform, including BHV-7000, subject to closing conditions including Hart-Scott-Rodino review. All clinical and nonclinical data, including metabolite characterization, were disclosed to SK Biopharmaceuticals before signing.
Biohaven Ltd. (BHVN) announced a strategic global license and collaboration under which its wholly owned subsidiary Biohaven Bioscience Ireland Limited will grant SK Biopharmaceuticals an exclusive, royalty-bearing worldwide license to Biohaven’s Kv7 ion channel platform, led by opakalim (BHV-7000), for epilepsy and other indications, effective upon closing.
SK Biopharmaceuticals will pay Biohaven $400 million in near-term cash (including $350 million at closing and $50 million one year later) and up to $150 million in development and regulatory milestones, plus tiered royalties on global net sales of opakalim and other licensed products. SK Biopharmaceuticals will also reimburse certain pre-closing costs and fund agreed development activities while Biohaven completes ongoing Phase 2/3 RISE 2 and RISE 3 trials and prepares an NDA for opakalim.
In a related agreement, SK Biopharmaceuticals will assume up to $245 million in contingent milestone obligations and a mid‑single‑digit worldwide royalty owed under a prior acquisition agreement for the Kv7 platform. Closing is subject to antitrust review, including under the Hart‑Scott‑Rodino Act, and other customary conditions.
Biohaven Ltd. director John Yetimoglu reported initial indirect ownership of 6,250,000 Common Shares of Biohaven Ltd. These shares are held by Infinitum Cayman Master, Ltd., over which Mr. Yetimoglu, as Chief Investment Officer of Infinitum Partners, GP LLC, may be deemed to have voting and investment control. He disclaims beneficial ownership of the shares except to the extent of his pecuniary interests in that entity.
Woodline Partners LP, a Delaware limited partnership and investment adviser to Woodline Master Fund LP and Woodline Spire Master Fund LP, reports beneficial ownership of 7,660,280 Common Shares of Biohaven Ltd. This represents 5.1% of the outstanding Common Shares.
Woodline Partners has sole voting and sole dispositive power over 7,660,280 shares and no shared voting or dispositive power. The ownership percentage is based on 150,560,990 Common Shares outstanding as of April 30, 2026, as reported by Biohaven Ltd.
Biohaven Ltd. reported second quarter 2026 results alongside extensive R&D updates across immunology, epilepsy, obesity, neuroscience and oncology. The company highlighted its extracellular protein degrader platforms (MoDE and TRAP), including BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy, both showing deep, rapid reductions in disease-driving antibodies with favorable safety profiles and progressing toward or into pivotal trials in 2026.
Opakalim (BHV-7000) demonstrated durable seizure control across multiple epilepsy types with a differentiated tolerability profile, with topline Phase 2/3 focal epilepsy data expected in the second half of 2026. Oncology programs BHV-1530 and BHV-1510 continue under collaborations with Regeneron, while additional pipeline assets taldefgrobep alfa, BHV-8100 and BHV-8000 advance in obesity, neuroimmunology and Parkinson’s disease.
Financially, cash, cash equivalents, marketable securities and restricted cash totaled approximately $270.5 million as of June 30, 2026. Second quarter R&D expenses decreased to $100.8 million from $184.4 million a year earlier, and net loss narrowed to $137.3 million, or $0.91 per share, with non-GAAP adjusted net loss of $118.1 million, or $0.78 per share.
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on immunology, obesity, neuroscience and oncology, reporting continued losses as it advances a broad R&D portfolio. For the quarter ended June 30, 2026, it recorded a net loss of $137.3 million and for the first half of 2026 a net loss of $267.8 million, driven primarily by research and development expense of $204.6 million over six months. Losses narrowed versus 2025 as R&D spending declined.
Liquidity is anchored by cash, cash equivalents and marketable securities of $267.9 million as of June 30, 2026, with management expecting these resources to fund operations for at least one year from the financial statement issuance date. Operating cash outflows were $235.0 million in the first half, partially offset by $178.9 million of equity raised through at-the-market offerings. The balance sheet shows total assets of $370.7 million and notes payable at fair value of $259.5 million under a revenue- and milestone-based Note Purchase Agreement tied to troriluzole, contributing to fair value losses in other expense. Shareholders’ equity declined to $12.2 million as accumulated deficit increased to $2.35 billion and the company continues to rely on external capital, including a large remaining ATM capacity.
Biohaven Ltd. appointed John Yetimoglu to its Board of Directors, effective August 6, 2026. He will serve in the director class whose term expires at the 2027 Annual Meeting of Shareholders and has been named to the Board’s Nominating and Governance Committee. The company states there is no arrangement or understanding with any other person regarding his selection, no family relationships with other directors or executive officers, and no related-party transactions involving him that require disclosure under Item 404(a) of Regulation S‑K.
Under Biohaven’s compensation policy for non‑employee directors, Mr. Yetimoglu is entitled to options to purchase common shares with an aggregate grant date fair value of $713,875, vesting 25% on grant and 25% on each of the following three anniversaries of grant, subject to his continuous service. He will also receive a $57,000 annual retainer for his service as a director and committee member.
Biohaven Ltd. officer Warren Karl Volles filed an initial statement of beneficial ownership. As of July 9, 2026, he directly owned 248,212 Common Shares, including shares acquired through the Biohaven Employee Share Purchase Plan. He also held 14,000 restricted share units and stock options over Common Shares, including options on 300,000 shares at $7.00 expiring in 2032 and on 95,250 shares at $41.93 expiring in 2034, with additional option tranches vesting through 2029.
Biohaven Ltd. announced several scientific leadership changes. Effective July 13, 2026, Bruce Car, Ph.D., will retire as Chief Scientific Officer and move to a part-time role as Chief Innovation Officer, focusing on scientific initiatives and external collaborations, including multiple assets in the collaboration with Bexorg, Inc. He will continue as an executive officer and his salary will be reduced by fifty percent to reflect his schedule.
At the same time, David Pirman, Ph.D., is promoted to Executive Vice President and Head of Discovery, leading Biohaven’s internal drug-discovery organization and research programs. The company also designated Warren Volles, General Counsel and Chief Legal Officer, as an executive officer, formalizing his role in guiding Biohaven’s legal function.